A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored clo

Trial Details

NCT ID
NCT06730347
Phase
PHASE2
Sponsor
MacroGenics
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Lorigerlimab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • New Orleans, Louisiana, United States|29.95465,-90.07507
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologically confirmed high-grade serous epithelial ovarian cancer, including primary peritoneal, or fallopian tube cancer, resistant to platinum…
  • Histologically confirmed clear cell carcinoma of the ovary (including primary peritoneal and fallopian tube), endometrium, vagina, vulva, or cervix.
  • Persistent or recurrent disease with documented disease progression.
  • Participants with PROC must have received at least 1 but not more than 3 prior lines of therapy for PROC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →